… This analysis shows that elderly patients can have as much benefit from second-line cytotoxic
chemotherapy as younger patients, and this can be achieved with acceptable toxicity rates…

… advanced cancer, an increasing number of elderly patients will be treated with immunotherapy.
… of nivolumab in an elderly patient population. Methods: Eligible patients recieved at least …

… elderly patients with checkpoint inhibition presents a unique challenge as nearly half of all
malignancies are diagnosed in patients … challenging in older patients given the association of …

… patients receiving erlotinib, irrespective of their individual characteristics (14). In this subset
analysis, we evaluated the association of age with the treatment results of erlotinib in patients …

… The results of these subset analyses show no statistically significant benefit (OS and DFS)
for the addition of oxaliplatin to FL as adjuvant treatment for either stage II and elderly patients. …

… , at 2.6% compared with 10.3% in middle-aged and 24.4% in elderly patients. The
incidence of reinfarction during the1 year of follow-up was similar in all subsets. The statistical …

… for elderly patients with lung cancer, we present the data from a subset analysis that
focused on the efficacy, toxicity, and HRQoL in elderly patients included in the phase III trial. …

… A recently conducted pharmacokinetic study in elderly patients undergoing orthopedic
surgery suggests that a dose regimen adjustment may be appropriate in the patient group older …

… Because sorafenib is likely to be used in elderly pts with advanced RCC, we evaluated
its safety and efficacy profile in a subset of pts ≥65 years (yrs) who enrolled in the ARCCS …

… We performed a retrospective analysis of elderly patient subsets (aged ≥65 and ≥70 years)
within a phase III trial evaluating pemetrexed + carboplatin and docetaxel + carboplatin in …